RESUMEN
Gastro-oesophageal reflux disease (GORD) has long been associated with poor asthma control without an established cause-effect relationship. 610 asthmatics (421 severe/88 mild-moderate) and 101 healthy controls were assessed clinically and a subset of 154 severe asthmatics underwent proteomic analysis of induced sputum using untargeted mass spectrometry, LC-IMS-MSE. Univariate and multiple logistic regression analyses (MLR) were conducted to identify proteins associated with GORD in this cohort. When compared to mild/moderate asthmatics and healthy individuals, respectively, GORD was three- and ten-fold more prevalent in severe asthmatics and was associated with increased asthma symptoms and oral corticosteroid use, poorer quality of life, depression/anxiety, obesity and symptoms of sino-nasal disease. Comparison of sputum proteomes in severe asthmatics with and without active GORD showed five differentially abundant proteins with described roles in anti-microbial defences, systemic inflammation and epithelial integrity. Three of these were associated with active GORD by multiple linear regression analysis: Ig lambda variable 1-47 (pâ¯=â¯0·017) and plasma protease C1 inhibitor (pâ¯=â¯0·043), both in lower concentrations, and lipocalin-1 (pâ¯=â¯0·034) in higher concentrations in active GORD. This study provides evidence which suggests that reflux can cause subtle perturbation of proteins detectable in the airways lining fluid and that severe asthmatics with GORD may represent a distinct phenotype of asthma.
Asunto(s)
Asma/complicaciones , Asma/metabolismo , Reflujo Gastroesofágico/complicaciones , Proteómica/métodos , Esputo/metabolismo , Adulto , Asma/epidemiología , Asma/psicología , Endopeptidasas/metabolismo , Unión Europea/organización & administración , Femenino , Reflujo Gastroesofágico/diagnóstico , Reflujo Gastroesofágico/epidemiología , Humanos , Cadenas lambda de Inmunoglobulina/metabolismo , Lipocalina 1/metabolismo , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Prospectivos , Inhibidores de Proteasas/metabolismo , Calidad de Vida , Índice de Severidad de la EnfermedadRESUMEN
Rheumatoid arthritis (RA) is an immune-mediated inflammatory disease affecting the joints. A heterogeneous response to available therapies demonstrates the need to identify those patients likely to benefit from a particular therapy. Our objective was to identify genetic factors associated with response to tocilizumab, a humanized monoclonal antibody targeting the interleukin (IL)-6 receptor, recently approved for treating RA. We report the first genome-wide association study on the response to tocilizumab in 1683 subjects with RA from six clinical studies. Putative associations were identified with eight loci, previously unrecognized as linked to the IL-6 pathway or associated with RA risk. This study suggests that it is unlikely that a major genetic determinant of response exists, and it illustrates the complexity of performing genome-wide association scans in clinical trials.
Asunto(s)
Anticuerpos Monoclonales Humanizados/administración & dosificación , Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/genética , Interleucina-6/genética , Adulto , Antirreumáticos/administración & dosificación , Artritis Reumatoide/patología , Ensayos Clínicos Fase III como Asunto , Femenino , Estudio de Asociación del Genoma Completo , Humanos , Interleucina-6/metabolismo , Masculino , Metotrexato/administración & dosificación , Persona de Mediana Edad , Polimorfismo de Nucleótido SimpleRESUMEN
The objective of pharmacogenetic research is to identify a genetic marker, or a set of genetic markers, that can predict how a given person will respond to a given medicine. To search for such marker combinations that are predictive of adverse drug events, we have developed and applied two complementary methods to a pharmacogenetic study of the hypersensitivity reaction (HSR) associated with treatment with abacavir, a medicine that is used to treat HIV-infected patients. Our results show that both of these methods can be used to uncover potentially useful predictive marker combinations. The pairwise marker combination method yielded a collection of marker pairs that featured a spectrum of sensitivities and specificities. Recursive partitioning results led to the genetic delineation of multiple risk categories, including those with extremely high and extremely low risk of HSR. These methods can be readily applied in pharmacogenetic candidate gene studies as well as in genome-wide scans.